Efficacy and Safety of New Mometasone Furoate Nasal Spray Formulation in Acute Rhinosinusitis Patients: A Randomized Clinical Trial

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 10, 2022

Primary Completion Date

November 6, 2022

Study Completion Date

November 6, 2022

Conditions

Acute Rhinosinusitis

Interventions

DRUG

Mometasone Nasal 50 Mcg/Inh Nasal Spray

Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.

DEVICE

Nasal spray

device can work properly for actuation during trials

Trial Locations (1)

Saffron Pharmaceutical, Faisalabad